Four years after Sanofi shelled out $125 million for global rights to Biond Biologic | The company is handing back the tumor ...

Sanofi has shared a deeper dive into its 469 million euro ($491 million) bowel disease bet, publishing phase 2 data that ...

Sanofi and Teva Pharmaceuticals have reported new outcomes from the randomised Phase IIb RELIEVE UCCD trial of human ...

Teva and Sanofi's duvakitug showed promising results in a Phase 2b study for ulcerative colitis and Crohn's disease, with ...

Previous bird flu outbreaks and decades-old public health infrastructure have led industry to protect the hens used for ...

Following similar deals in countries like the United States and the U.K., Canada is bolstering its stockpile of bird flu ...

ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s diseaseNew detailed data from the RELIEVE UCCD ...

Sanofi and Teva Pharmaceuticals have reported ... The double-blinded, 14-week, dose-ranging study was designed to assess the safety, pharmacokinetics, tolerability and efficacy of the antibody ...

Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be ...

Flu vaccine makers may face a last-minute scramble to produce enough doses after an FDA advisory committee meeting was ...

Merilog’s approval comes as the insulin space has over the past year suffered several setbacks, including strong calls for price caps and, potentially, the rise of the mammoth GLP-1 market.